2seventy bio (TSVT) Stock Forecast, Price Target & Predictions
TSVT Stock Forecast
2seventy bio stock forecast is as follows: an average price target of $2.00 (represents a -58.33% downside from TSVT’s last price of $4.80) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
TSVT Price Target
The average price target for 2seventy bio (TSVT) is $2.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $2.00 to $2.00. This represents a potential -58.33% downside from TSVT's last price of $4.80.
TSVT Analyst Ratings
According to 7 Wall Street analysts, 2seventy bio's rating consensus is 'Buy'. The analyst rating breakdown for TSVT stock is 0 'Strong Buy' (0.00%), 5 'Buy' (71.43%), 1 'Hold' (14.29%), 1 'Sell' (14.29%), and 0 'Strong Sell' (0.00%).
2seventy bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 06, 2024 | Salveen Richter | Goldman Sachs | $2.00 | $4.56 | -56.14% | -58.33% |
| May 02, 2022 | - | Goldman Sachs | $26.00 | $13.46 | 93.16% | 441.67% |
The latest 2seventy bio stock forecast, released on Jun 06, 2024 by Salveen Richter from Goldman Sachs, set a price target of $2.00, which represents a -56.14% decrease from the stock price at the time of the forecast ($4.56), and a -58.33% decrease from TSVT last price ($4.80).
2seventy bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $2.00 |
| Last Closing Price | $4.80 | $4.80 | $4.80 |
| Upside/Downside | -100.00% | -100.00% | -58.33% |
In the current month, the average price target of 2seventy bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to 2seventy bio's last price of $4.80. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 06, 2024 | Goldman Sachs | Buy | Sell | Downgrade |
| Apr 07, 2024 | Citigroup | Buy | Buy | Hold |
| Jan 31, 2024 | Leerink Partners | - | Outperform | Upgrade |
| Sep 13, 2023 | Guggenheim | - | Neutral | Downgrade |
| Mar 17, 2023 | Wedbush | Outperform | Outperform | Hold |
| Jan 10, 2023 | SVB Leerink | Outperform | Outperform | Hold |
| May 02, 2022 | Goldman Sachs | - | Buy | Initialise |
| Apr 26, 2022 | Zacks Investment Research | - | Buy | Upgrade |
2seventy bio's last stock rating was published by Goldman Sachs on Jun 06, 2024. The company Downgrade its TSVT rating from "Buy" to "Sell".
2seventy bio Financial Forecast
2seventy bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $12.03M | - | $41.62M | $56.18M | $13.41M | - | $8.43M | $16.03K | $19.26M |
| Avg Forecast | $14.10M | $13.60M | $12.50M | $12.00M | $12.05M | $10.58M | $11.08M | $14.92M | $14.71M | $31.18M | $36.84M | $21.25M | $15.27M | $12.37M | $16.52M | $19.73M | $12.92M | $8.52M |
| High Forecast | $34.36M | $33.14M | $30.46M | $29.24M | $29.36M | $10.92M | $27.00M | $36.35M | $23.72M | $75.97M | $89.78M | $51.78M | $37.21M | $30.13M | $16.52M | $27.09M | $17.74M | $11.69M |
| Low Forecast | $6.45M | $6.22M | $5.72M | $5.49M | $5.51M | $10.23M | $5.07M | $6.83M | $7.72M | $14.27M | $16.86M | $9.73M | $6.99M | $5.66M | $16.52M | $14.61M | $9.57M | $6.31M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.39% | - | 1.96% | 3.68% | 1.08% | - | 0.43% | 0.00% | 2.26% |
2seventy bio's average Quarter revenue forecast for Dec 23 based on 5 analysts is $14.71M, with a low forecast of $7.72M, and a high forecast of $23.72M. TSVT's average Quarter revenue forecast represents a 22.20% increase compared to the company's last Quarter revenue of $12.03M (Sep 23).
2seventy bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-33.76M | - | $-49.31M | $-24.79M | $-65.89M | - | $-86.96M | $11.62M | $-55.33M |
| Avg Forecast | $-12.57M | $-12.12M | $-11.14M | $-10.70M | $-10.74M | $-9.43M | $-9.88M | $-13.30M | $-13.11M | $-27.79M | $-32.84M | $-18.94M | $-13.61M | $-11.02M | $-14.73M | $-17.59M | $-11.52M | $-7.59M |
| High Forecast | $-5.75M | $-5.55M | $-5.10M | $-4.90M | $-4.92M | $-9.12M | $-4.52M | $-6.09M | $-6.88M | $-12.72M | $-15.03M | $-8.67M | $-6.23M | $-5.04M | $-14.73M | $-13.02M | $-8.53M | $-5.62M |
| Low Forecast | $-30.63M | $-29.54M | $-27.15M | $-26.06M | $-26.17M | $-9.73M | $-24.06M | $-32.40M | $-21.15M | $-67.72M | $-80.03M | $-46.15M | $-33.17M | $-26.86M | $-14.73M | $-24.15M | $-15.82M | $-10.42M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.21% | - | 2.60% | 1.82% | 5.98% | - | 4.94% | -1.01% | 7.29% |
1 analysts predict TSVT's average Quarter EBITDA for Mar 22 to be $-17.59M, with a high of $-13.02M and a low of $-24.15M. This is -251.32% lower than 2seventy bio's previous annual EBITDA (Dec 21) of $11.62M.
2seventy bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | $-71.64M | - | $-42.48M | $-23.14M | $-67.44M | - | $-80.93M | $-60.97K | $-60.00M |
| Avg Forecast | $-14.85M | $-15.40M | $-15.95M | $-16.50M | $-11.84M | $-14.59M | $-36.63M | $-41.04M | $-56.94M | $-63.21M | $-56.74M | $-69.08M | $-85.58M | $-97.21M | $-111.95M | $-108.16M | $-140.48M | $-127.94M |
| High Forecast | $-4.38M | $-4.54M | $-4.71M | $-4.87M | $-3.49M | $-4.30M | $-10.80M | $-12.11M | $-43.41M | $-18.64M | $-16.74M | $-20.37M | $-25.24M | $-28.67M | $-111.95M | $-71.68M | $-93.09M | $-84.78M |
| Low Forecast | $-42.59M | $-44.17M | $-45.75M | $-47.32M | $-33.94M | $-41.83M | $-105.03M | $-117.69M | $-63.94M | $-181.26M | $-162.71M | $-198.09M | $-245.41M | $-278.76M | $-111.95M | $-160.65M | $-208.66M | $-190.03M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.13% | - | 0.61% | 0.27% | 0.69% | - | 0.75% | 0.00% | 0.47% |
2seventy bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TSVT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
2seventy bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | $13.00M | - | $20.72M | $18.70M | $19.61M | - | $23.86M | $24.48K | $23.00M |
| Avg Forecast | $15.47M | $14.92M | $13.71M | $13.16M | $13.22M | $11.60M | $12.15M | $16.36M | $16.13M | $34.20M | $40.41M | $23.31M | $16.75M | $13.56M | $18.13M | $21.64M | $14.17M | $9.34M |
| High Forecast | $37.68M | $36.35M | $33.41M | $32.07M | $32.21M | $11.98M | $29.61M | $39.87M | $26.02M | $83.32M | $98.47M | $56.79M | $40.82M | $33.05M | $18.13M | $29.72M | $19.46M | $12.83M |
| Low Forecast | $7.08M | $6.83M | $6.27M | $6.02M | $6.05M | $11.22M | $5.56M | $7.49M | $8.47M | $15.65M | $18.50M | $10.67M | $7.67M | $6.21M | $18.13M | $16.02M | $10.49M | $6.92M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.38% | - | 0.89% | 1.12% | 1.45% | - | 1.10% | 0.00% | 2.46% |
2seventy bio's average Quarter SG&A projection for Dec 23 is $16.13M, based on 5 Wall Street analysts, with a range of $8.47M to $26.02M. The forecast indicates a 24.04% rise compared to TSVT last annual SG&A of $13.00M (Sep 23).
2seventy bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | $-1.40 | - | $-0.98 | $-649.41 | $-1.75 | - | $-3.03 | $-0.00 | $-2.58 |
| Avg Forecast | $-0.27 | $-0.28 | $-0.29 | $-0.30 | $-0.22 | $-0.27 | $-0.67 | $-0.75 | $-1.04 | $-1.15 | $-1.03 | $-1.26 | $-1.56 | $-1.77 | $-2.15 | $-2.10 | $-2.73 | $-2.49 |
| High Forecast | $-0.08 | $-0.08 | $-0.09 | $-0.09 | $-0.06 | $-0.08 | $-0.20 | $-0.22 | $-0.79 | $-0.34 | $-0.30 | $-0.37 | $-0.46 | $-0.52 | $-2.15 | $-1.39 | $-1.81 | $-1.65 |
| Low Forecast | $-0.77 | $-0.80 | $-0.83 | $-0.86 | $-0.62 | $-0.76 | $-1.91 | $-2.14 | $-1.16 | $-3.30 | $-2.96 | $-3.60 | $-4.46 | $-5.07 | $-2.15 | $-3.13 | $-4.06 | $-3.70 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.22% | - | 0.78% | 417.44% | 0.99% | - | 1.44% | 0.00% | 1.03% |
According to undefined Wall Street analysts, 2seventy bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TSVT previous annual EPS of $NaN (undefined).
2seventy bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KZR | Kezar Life Sciences | $0.58 | $17.50 | 2917.24% | Buy |
| ZNTL | Zentalis Pharmaceuticals | $4.10 | $21.86 | 433.17% | Buy |
| PLRX | Pliant Therapeutics | $12.60 | $39.71 | 215.16% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.76 | $38.80 | 181.98% | Buy |
| RLAY | Relay Therapeutics | $7.60 | $19.40 | 155.26% | Buy |
| INZY | Inozyme Pharma | $5.83 | $14.67 | 151.63% | Buy |
| STOK | Stoke Therapeutics | $15.12 | $33.75 | 123.21% | Buy |
| REPL | Replimune Group | $11.03 | $24.20 | 119.40% | Buy |
| RCUS | Arcus Biosciences | $16.73 | $35.20 | 110.40% | Buy |
| IOVA | Iovance Biotherapeutics | $10.42 | $21.57 | 107.01% | Buy |
| SNDX | Syndax Pharmaceuticals | $18.06 | $36.00 | 99.34% | Buy |
| CGEM | Cullinan Oncology | $17.24 | $32.00 | 85.61% | Buy |
| MRSN | Mersana Therapeutics | $2.04 | $3.00 | 47.06% | Buy |
| PHAT | Phathom Pharmaceuticals | $18.49 | $25.83 | 39.70% | Buy |
| SRPT | Sarepta Therapeutics | $125.69 | $169.93 | 35.20% | Buy |
| CRNX | Crinetics Pharmaceuticals | $52.99 | $70.14 | 32.36% | Buy |
| ASND | Ascendis Pharma | $146.59 | $189.07 | 28.98% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| PTGX | Protagonist Therapeutics | $44.91 | $50.00 | 11.33% | Buy |
| KDNY | Chinook Therapeutics | $40.39 | $30.00 | -25.72% | Buy |
| TSVT | 2seventy bio | $4.80 | $2.00 | -58.33% | Buy |
TSVT Forecast FAQ
Is 2seventy bio a good buy?
Yes, according to 7 Wall Street analysts, 2seventy bio (TSVT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 71.43% of TSVT's total ratings.
What is TSVT's price target?
2seventy bio (TSVT) average price target is $2 with a range of $2 to $2, implying a -58.33% from its last price of $4.8. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will 2seventy bio stock go up soon?
According to Wall Street analysts' prediction for TSVT stock, the company can go down by -58.33% (from the last price of $4.8 to the average price target of $2), down by -58.33% based on the highest stock price target, and down by -58.33% based on the lowest stock price target.
Can 2seventy bio stock reach $7?
TSVT's average twelve months analyst stock price target of $2 does not support the claim that 2seventy bio can reach $7 in the near future.
What are 2seventy bio's analysts' financial forecasts?
2seventy bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $48.62M (high $103.63M, low $27.64M), average EBITDA is $-43.344M (high $-24.639M, low $-92.374M), average net income is $-104M (high $-30.701M, low $-298M), average SG&A $53.34M (high $113.67M, low $30.32M), and average EPS is $-1.892 (high $-0.558, low $-5.426). TSVT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $52.2M (high $127.19M, low $23.89M), average EBITDA is $-46.531M (high $-21.295M, low $-113M), average net income is $-62.713M (high $-18.497M, low $-180M), average SG&A $57.26M (high $139.51M, low $26.2M), and average EPS is $-1.14 (high $-0.336, low $-3.269).
Did the TSVT's actual financial results beat the analysts' financial forecasts?
Based on 2seventy bio's last annual report (Dec 2023), the company's revenue was $100.39M, which missed the average analysts forecast of $103.98M by -3.45%. Apple's EBITDA was $-238M, beating the average prediction of $-92.686M by 156.36%. The company's net income was $-218M, missing the average estimation of $-246M by -11.55%. Apple's SG&A was $69.41M, missing the average forecast of $114.05M by -39.14%. Lastly, the company's EPS was $-4.42, missing the average prediction of $-4.471 by -1.15%. In terms of the last quarterly report (Sep 2023), 2seventy bio's revenue was $12.03M, missing the average analysts' forecast of $31.18M by -61.40%. The company's EBITDA was $-33.758M, beating the average prediction of $-27.791M by 21.47%. 2seventy bio's net income was $-71.638M, beating the average estimation of $-63.21M by 13.33%. The company's SG&A was $13M, missing the average forecast of $34.2M by -61.97%. Lastly, the company's EPS was $-1.4, beating the average prediction of $-1.149 by 21.84%